Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Cai

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Journal of Medical Economics|June 30, 2016
Comparative persistence and adherence with newer anti-hyperglycemic agents to treat patients with type 2 diabetes in the United StatesJennifer Cai, Yuexi Wang, Onur Baser, et al.
The Patient|January 10, 2018
Impact of Canagliflozin Treatment on Health-Related Quality of Life among People with Type 2 Diabetes Mellitus: A Pooled Analysis of Patient-Reported Outcomes from Randomized Controlled TrialsJennifer Cai, Linda M Delahanty, Sydney Akapame, et al.
Clinical Case Reports|May 6, 2024
Unusual painful pelvic masses: Extramedullary hematopoiesis with extramedullary multiple myelomaJennifer Cai, Marian Varda, David Sin, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|April 1, 2017
The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozinNicole M Gerlanc, Jennifer Cai, Joseph Tkacz, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|January 30, 2015
Economic burden of recurrent venous thromboembolism: analysis from a U.S. hospital perspectiveJulian P Casciano, Zenobia Dotiwala, Robert Kemp, et al.
Current Medical Research and Opinion|April 20, 2018
The impact of non-medical switch on type 2 diabetes patients treated with canagliflozin in the commercially insured US populationLawrence Blonde, Chakkarin Burudpakdee, Victoria Divino, et al.
Journal of Hematology|November 4, 2024
Transformation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma to Histiocytic/Dendritic Cell SarcomaJennifer Cai, David Fernandez-Hazoury, Gene Yoshikawa, et al.
Journal of Comparative Effectiveness Research|June 7, 2019
Treatment patterns, glycemic control and bodyweight with canagliflozin 300 mg versus GLP1RAs in Type II diabetes patientsCraig I Coleman, Shivani Pandya, Li Wang, et al.
Journal of Oncology Practice|September 8, 2016
Increase in Cancer Center Staff Effort Related to Electronic Patient Portal UseAndrew L Laccetti, Beibei Chen, Jennifer Cai, et al.
Journal of Medical Economics|July 19, 2021
Quantifying spillover benefits in value assessment: a case study of increased graft survival on the US kidney transplant waitlistSyvart Dennen, Oliver Díaz Espinosa, Kelly Birch, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Journal of Medical Economics|June 30, 2016
Comparative persistence and adherence with newer anti-hyperglycemic agents to treat patients with type 2 diabetes in the United StatesJennifer Cai, Yuexi Wang, Onur Baser, et al.
The Patient|January 10, 2018
Impact of Canagliflozin Treatment on Health-Related Quality of Life among People with Type 2 Diabetes Mellitus: A Pooled Analysis of Patient-Reported Outcomes from Randomized Controlled TrialsJennifer Cai, Linda M Delahanty, Sydney Akapame, et al.
Clinical Case Reports|May 6, 2024
Unusual painful pelvic masses: Extramedullary hematopoiesis with extramedullary multiple myelomaJennifer Cai, Marian Varda, David Sin, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|April 1, 2017
The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozinNicole M Gerlanc, Jennifer Cai, Joseph Tkacz, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|January 30, 2015
Economic burden of recurrent venous thromboembolism: analysis from a U.S. hospital perspectiveJulian P Casciano, Zenobia Dotiwala, Robert Kemp, et al.
Current Medical Research and Opinion|April 20, 2018
The impact of non-medical switch on type 2 diabetes patients treated with canagliflozin in the commercially insured US populationLawrence Blonde, Chakkarin Burudpakdee, Victoria Divino, et al.
Journal of Hematology|November 4, 2024
Transformation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma to Histiocytic/Dendritic Cell SarcomaJennifer Cai, David Fernandez-Hazoury, Gene Yoshikawa, et al.
Journal of Comparative Effectiveness Research|June 7, 2019
Treatment patterns, glycemic control and bodyweight with canagliflozin 300 mg versus GLP1RAs in Type II diabetes patientsCraig I Coleman, Shivani Pandya, Li Wang, et al.
Journal of Oncology Practice|September 8, 2016
Increase in Cancer Center Staff Effort Related to Electronic Patient Portal UseAndrew L Laccetti, Beibei Chen, Jennifer Cai, et al.
Journal of Medical Economics|July 19, 2021
Quantifying spillover benefits in value assessment: a case study of increased graft survival on the US kidney transplant waitlistSyvart Dennen, Oliver Díaz Espinosa, Kelly Birch, et al.
Pageof 4